Tradestie Institutional Equity Comparison Engine · Market Close Nov 20, 2026

MXCT vs TMCI: Which Stock Is the Better Buy Now?

Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.

TMCI Wins Head-to-Head Institutional Verdict (5–0 across 6 Pillars · 5–3 Matrix Metrics)

TMCI Overall Winner 6-Pillar Tally: MXCT 0 – 5 TMCI (1 Tie) Matrix Metrics: MXCT 3 – 5 TMCI

As of Nov 20, 2026, Treace Medical Concepts, Inc. (TMCI) is the stronger overall head-to-head candidate over MaxCyte, Inc. (MXCT) in the Tradestie Institutional Equity Comparison Engine, winning 5–3 core matrix metrics and 5–0 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Profitability & Quality). MXCT carries a Unified Composite Score of 41.7/100 (SELL) at $1.37 (N/M Forward P/E, -85.5% operating margin), whereas TMCI carries 42.7/100 (HOLD) at $4.31 (N/M Forward P/E, -24.4% operating margin).

  • Growth vs. Quality Trade-Off: TMCI earns the overall head-to-head edge with a stronger Unified Composite Score (42.7/100 HOLD vs. MXCT 41.7/100 SELL) and 2.03β · 110% Vol risk profile, whereas MXCT leads top-line expansion (+48.7% YoY revenue growth, N/M PEG, and 0 of 6 institutional pillars) for higher-beta growth mandates.
  • Technical & Structure Timing Caution: MXCT trades in a Markup technical trend (UNCLASSIFIED options phase, RSI 55.3); meanwhile TMCI is in a Weinstein Distribution regime near a flattening 50-day moving average (RSI 46.1). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

Executive Snapshot Side-by-Side Composite Ratings & Technical Regime

Ask Alpha AI About MXCT vs TMCI
MXCT NASDAQ
MaxCyte, Inc. Common Stock
Services-Commercial Physical & Biological Research
$1.37
+7.03% 1D
Market Cap $132.2M
TTM Revenue $34M
Forward P/E N/M
Beta / 30D Vol 1.19β · 96% Vol
Unified Composite Score
41.7 / 100 SELL
Tech 46.0 Fund 52.0 Flow 62.0 Mom 50.0
Weinstein Technical Phase Markup · Hold / add on dips
Price above SMA50, rising 50-day trend (2.1% over 20 days), RSI 55
RSI-14: 55.3 · SMA20: $1.36 · SMA50: $1.25
TMCI NASDAQ Head-to-Head Winner
Treace Medical Concepts, Inc. Common Stock
Surgical & Medical Instruments & Apparatus
$4.31
-0.92% 1D
Market Cap $285.2M
TTM Revenue $203M
Forward P/E N/M
Beta / 30D Vol 2.03β · 110% Vol
Unified Composite Score
42.7 / 100 HOLD
Tech 25.0 Fund 45.0 Flow 67.0 Mom 50.0
Weinstein Technical Phase Distribution · Trim / tighten stop
Price near a flattening SMA50 (slope -0.0%) with fading momentum, RSI 46
RSI-14: 46.1 · SMA20: $4.60 · SMA50: $4.41

6-Pillar Scorecard Institutional Category Breakdown (MXCT 0 – 5 TMCI)

Columns: Metric · MXCT · TMCI
1. Valuation Multiples TMCI
Forward P/E N/M N/M
Trailing P/E N/M N/M
PEG Ratio N/M N/M
EV / Revenue 3.9x 1.7x
2. Growth & Scale TMCI
Revenue Growth (YoY) +48.7% -3.9%
Earnings Growth (YoY) +0.0% +0.0%
TTM Revenue (USD) $34M $203M
Market Cap $132.2M $285.2M
3. Profitability & Quality TMCI
Gross Margin 81.0% 79.6%
Operating Margin -85.5% -24.4%
Net Profit Margin -81.4% -27.4%
Return on Equity (ROE) -16.9% -74.0%
4. Balance Sheet & Cash Flow TMCI
Cash Generation (TTM) -$24M -$19M
Cash Flow Margin -69.2% -9.1%
Net Cash / Leverage $2.2M Net Debt (0.11x D/E) $67M Net Debt (1.21x D/E)
Dividend Yield None (0.00%) None (0.00%)
5. Options & Positioning TMCI
Options Structure Phase UNCLASSIFIED CONSOLIDATION
Current IV / %ile N/A (N/A) 547.9% (100th %ile)
Put/Call OI Skew N/A 0.34x (Call-Skewed)
OBV Trend / Tech Phase NEUTRAL · Markup NEUTRAL · Distribution
6. R&D & Supply-Chain Moat Tie
OpEx & R&D Intensity N/A N/A
90D R&D Disclosures 0 papers 0 papers
Competitive Moat Cyclical / Execution-Driven Positioning Cyclical / Execution-Driven Positioning
Supply-Chain Role Medical Devices Operator Medical Devices Operator

Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table

Core Matrix Wins: MXCT (3) vs TMCI (5)
Institutional Metric MXCT TMCI Criterion Row Edge
Market Capitalization
Scale
$132.2M $285.2M Larger Scale TMCI
Trailing P/E Ratio
Valuation
N/M N/M Lower Multiple Tie
Forward P/E Ratio
Valuation
N/M N/M Lower Multiple Tie
Revenue Growth (YoY)
Growth
+48.7% -3.9% Higher Growth MXCT
Operating Margin (TTM)
Profitability
-85.5% -24.4% Higher Margin TMCI
Net Profit Margin
Profitability
-81.4% -27.4% Higher Margin TMCI
Return on Equity (ROE)
Capital Efficiency
-16.9% -74.0% Higher ROE MXCT
52-Week Range Position
Momentum
63% ($1–$2) 74% ($1–$5) Stronger Trend TMCI
Beta / 30D Volatility
Risk Regime
1.19β · 96% Vol 2.03β · 110% Vol Lower Realized Risk MXCT
Unified Institutional Score
Composite Signal
41.7 / 100 (SELL) 42.7 / 100 (HOLD) Higher Composite TMCI
Trailing 12M Revenue (USD)
Operating Scale
$34M $203M FX-Normalized USD Scale
Gross Profit Margin (TTM)
Unit Pricing Power
81.0% 79.6% Higher Margin Quality
PEG Ratio & EV / Revenue
Growth-Adjusted Valuation
N/M PEG · 3.9x EV/Rev N/M PEG · 1.7x EV/Rev Lower Multiple Valuation
Cash Flow & Balance Sheet
Capital Self-Funding
-$24M ($2.2M Net Debt (0.11x D/E)) -$19M ($67M Net Debt (1.21x D/E)) Higher Cash / Net Cash Solvency

Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)

1M Horizon TMCI +4.9 pp
MXCT: -4.2% · TMCI: +0.7%
3M Horizon TMCI +0.07 pp
MXCT: -1.44% · TMCI: -1.37%
6M Horizon TMCI +23.31 pp
MXCT: +31.73% · TMCI: +55.04%
1Y Horizon TMCI +77.87 pp
MXCT: -19.41% · TMCI: +58.46%

Financial Trajectory Multi-Year Annual Revenue & Operating Margin Trajectory (USD)

Split-Invariant USD Revenue & Operating Margin (%)
Period MXCT Revenue TMCI Revenue MXCT Op. Margin TMCI Op. Margin Margin Leader
FY2019 $10M $40M -93.7% -9.0% TMCI
FY2020 $20M $60M -71.6% 1.5% TMCI
FY2021 $20M $90M -84.3% -17.5% TMCI
FY2022 $30M $140M -95.2% -24.6% TMCI
FY2023 $20M $190M -247.7% -27.5% TMCI
FY2024 $20M $210M -230.5% -26.6% TMCI
FY2025 $20M $210M -247.6% -25.5% TMCI

Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor

Live Options Phase Tracker
MXCT UNCLASSIFIED
0d in phase · OBV NEUTRAL
Current IV N/A
IV Percentile N/A
Put/Call OI Skew N/A
IV Regime Unclassified
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal BULLISH
OBV Flow NEUTRAL
Exact MXCT Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →
TMCI CONSOLIDATION
106d in phase · OBV NEUTRAL
Current IV 547.9%
IV Percentile 100th %ile
Put/Call OI Skew 0.34x (Call-Skewed)
IV Regime Extreme (>80th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal BEARISH
OBV Flow NEUTRAL
Exact TMCI Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →

Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity

Corporate R&D & Foundry Leaderboard
MXCT Moat Profile Cyclical / Execution-Driven Positioning
Medical Devices Operator
Competes within the Medical Devices value chain with $132.2M market capitalization and -85.5% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published
TMCI Moat Profile Cyclical / Execution-Driven Positioning
Medical Devices Operator
Competes within the Medical Devices value chain with $285.2M market capitalization and -24.4% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published

Investor FAQ MXCT vs TMCI Key Questions & Quantitative Answers

As of Nov 20, 2026, Treace Medical Concepts, Inc. (TMCI) is the stronger overall head-to-head candidate over MaxCyte, Inc. (MXCT) in the Tradestie Institutional Equity Comparison Engine, winning 5–3 core matrix metrics and 5–0 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Profitability & Quality). MXCT carries a Unified Composite Score of 41.7/100 (SELL) at $1.37 (N/M Forward P/E, -85.5% operating margin), whereas TMCI carries 42.7/100 (HOLD) at $4.31 (N/M Forward P/E, -24.4% operating margin). Growth vs. Quality Trade-Off: TMCI earns the overall head-to-head edge with a stronger Unified Composite Score (42.7/100 HOLD vs. MXCT 41.7/100 SELL) and 2.03β · 110% Vol risk profile, whereas MXCT leads top-line expansion (+48.7% YoY revenue growth, N/M PEG, and 0 of 6 institutional pillars) for higher-beta growth mandates. Technical & Structure Timing Caution: MXCT trades in a Markup technical trend (UNCLASSIFIED options phase, RSI 55.3); meanwhile TMCI is in a Weinstein Distribution regime near a flattening 50-day moving average (RSI 46.1). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

TMCI leads the Growth & Scale pillar: MXCT posts +48.7% YoY revenue growth and +0.0% YoY earnings growth on $34M TTM revenue (81.0% gross margin, -85.5% operating margin), compared with TMCI at -3.9% YoY revenue growth and +0.0% YoY earnings growth on $203M TTM revenue (79.6% gross margin, -24.4% operating margin). Across the 7-period historical trajectory (FY2019 to FY2025), MXCT cumulative revenue shifted +100.0% while TMCI shifted +425.0%. In operating R&D and SG&A reinvestment, MXCT deploys N/A (0 90-day corporate R&D disclosures) versus N/A (0 disclosures) for TMCI.

TMCI screens cheaper on headline valuation multiples. MXCT trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and 3.9x EV/Revenue (-69.2% FCF margin), whereas TMCI trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and 1.7x EV/Revenue (-9.1% FCF margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against MXCT (-16.9% ROE) versus TMCI (-74.0% ROE) capital efficiency.

In options market volatility and institutional positioning, MXCT carries N/A implied volatility (N/A, Unclassified), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (1.19β · 96% Vol realized risk). By comparison, TMCI carries 547.9% implied volatility (100th %ile, Extreme (>80th %ile)), a 0.34x (Call-Skewed) Put/Call open-interest ratio, NEUTRAL on-balance volume, and sits in a CONSOLIDATION options structure phase (2.03β · 110% Vol realized risk).

Cross-Compare 1-Click Peer Rivalries & Single-Stock Research

Launch Custom Ticker Comparison →

Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 20, 2026. For educational research only; not investment advice.